Related Experiment Video

Updated: Jul 18, 2026

Intramyocardial Cell Delivery: Observations in Murine Hearts
08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

Advances in the treatment of ST Elevation Myocardial Infarction in the UK

Lal Hussain Mughal1, Sanjay Sastry2

  • 1Senior Clinical Fellow in Interventional Cardiology, Wythenshawe Hospital, Manchester University Foundation Trust, UK.

JRSM Cardiovascular Disease
|February 21, 2022
PubMed

Insights

Primary percutaneous coronary intervention (PCI) improves outcomes for ST-elevation myocardial infarction (STEMI) patients within 12 hours of symptom onset. Treatment involves opening the blocked artery, often with a drug-eluting stent, and 12 months of antiplatelet medication.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Medicine

Background:

  • Primary percutaneous coronary intervention (PCI) is the standard treatment for ST-elevation myocardial infarction (STEMI) in the UK.
  • PCI has significantly improved patient outcomes over the past 15 years.
  • Timely revascularization is crucial for STEMI patients presenting within 12 hours of symptom onset.

Purpose of the Study:

  • To summarize the current standard of care for STEMI treatment.
  • To highlight the benefits of primary PCI and optimal medical management.
  • To discuss emerging evidence supporting comprehensive revascularization strategies.

Main Methods:

  • Review of current treatment guidelines and clinical evidence for STEMI.
  • Focus on primary PCI procedures, including stent selection and access site choice.
  • Analysis of post-procedure medication regimens and long-term follow-up.

Main Results:

  • Primary PCI within 150 minutes of call for help improves STEMI outcomes.
  • Drug-eluting stents followed by 12 months of antiplatelet therapy are standard.
  • Radial artery access is associated with better outcomes than femoral artery access.

Conclusions:

  • Primary PCI remains the gold standard for STEMI management.
  • Optimizing procedural techniques and medication adherence is key.
  • Full revascularization, addressing all significant stenoses, is increasingly supported by evidence.

Keywords:
STEMIacute coronary occlusionballoons and stentsprimary percutaneous coronary intervention

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
27
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
103
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
67
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
36
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
44
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
40